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Knowledge of the cagA status of Helicobacter pylori infection could be relevant for the
treatment and prevention of possible complications of infection. This goal can be
achieved using serology since CagA is highly immunogenic. The aim of this study
was to correlate the presence of the cagA gene detected by polymerase chain reaction
(PCR) with the presence of serum antibodies against the CagA protein using a recently
available commercial immunoblotting assay, the Helico Blot 2.1 kit. Considering the
results obtained by PCR, Helico Blot 2.1 presented sensitivity, speciﬁcity, and positive
and negative predictive values for CagA status of 97.4%, 87.7%, 80.9% and 98.5%,
respectively.
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Helicobacter pylori is a Gram-negative bacterium
involved in the pathogenesis of peptic ulcer dis-
ease, gastric carcinoma, and mucosa-associated
lymphoid tissue (MALT) lymphoma [1,2].
The high prevalence of infection throughout the
world (ranging from 20% in developed countries
to more than 90% in developing areas), compared
to the relatively low prevalence of these diseases,
raises the question of whether allH. pylori have the
same clinical impact [3] and suggests the impor-
tance of a search for markers to identify those
persons with a higher risk of developing severe
diseases.
Several H. pylori genes related to the risk of
disease have been identiﬁed [4]. The cytotoxin-
associated gene (cagA) is a marker for a genomic
pathogenicity island (cag PAI) of about 40 kilobase
pairs (kbp) [5], whose presence is associated with a
more severe clinical outcome of infection [6–8].
The cag PAI contains, among others, genes encod-
ing proteins that enhance the virulence of the
strain, for example, by increasing interleukin-8
production by host cells [9].
Knowledge of the cagA status of H. pylori infec-
tion could be relevant for the treatment and pre-
vention of possible complications of infection. It is
therefore important to diagnose the type of infect-
ing organism. This goal can be achieved using
serology since CagA is highly immunogenic
[10]; in fact, more than 95% of subjects infected
by cagA-positive H. pylori strains develop a sero-
logically detectable response against CagA [11]. A
number of reports have been published regarding
the association of anti-CagA antibodies with dif-
ferent diseases. Studies using puriﬁed proteins
and an enzyme-linked immunosorbent assay
(ELISA) for serological detection of antibodies
against CagA reported discrepancies between the
results of the ELISA andmolecular detection of the
cagA gene, with a tendency to overestimate the
prevalence of CagA-positiveH. pylori using ELISA
vs. colony hybridization. It is not clear whether the
discrepancy was due to simultaneous infections
with both cagA-positive and cagA-negative strains
or because of false-positive ELISA results [12].
The aim of this study was to correlate the pre-
sence of the cagA gene detected by polymerase
chain reaction (PCR) with the presence of serum
antibodies against the CagA protein using a
recently available commercial immunoblotting
assay, the Helico Blot 2.1 kit (Genelabs Diagnos-
tics, Singapore).
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Sera were obtained from consecutive patients
undergoing endoscopy who were already partici-
pating in a comparative study of non-invasive and
invasive methods for the diagnosis of H. pylori
infection. A total of 116 patients were enrolled
in the study. Of these, 52 (38 men, 14 women,
median age 48, range 20–77 years) were H. pylori
positive and 64 (40 men, 24 women, median age
51.7, range 17–87 years) were H. pylori negative.
A patient was classiﬁed as being H. pylori posi-
tive on the basis of either a positive culture or, in
the case of a negative culture, both a positive
histological examination and a positive urease test
(CLOtest1). A patient was classiﬁed as being H.
pylori negative when the culture, histological
examination and urease test were all negative.
Cases that were negative by culture but positive
in all the indirect tests were considered separately.
PCR with DNA from gastric biopsies and pri-
mers designed from the ure/glm gene and non-
invasive tests including as the urea breath test and
serological determination of anti-H. pylori immu-
noglobulin G (IgG) antibodies were also per-
formed. Patients with undeﬁned H. pylori status
based on invasive tests were classiﬁed using non-
invasive tests.
The Helico Blot 2.1 kit was used to detect IgG
antibodies to speciﬁc proteins of H. pylori accord-
ing to the manufacturer’s recommendations.
Helico Blot 2.1 is a serological test using a Western
Blot made from bacterial lysate and including a
recombinant antigen of H. pylori with a high pre-
dictive value for the indication of current H. pylori
infection. The corresponding bands to these pro-
teins are 116 kDa (CagA), 89 kDa (VacA), 37 kDa,
35 kDa, 30 kDa (ureA), 26.5 kDa and 19.5 kDa.
Anti-CagA antibodies are considered positive
when the 116 kDa (CagA) band, as well as at least
one or more of the other bands, are present. All
serological tests were performed on frozen mate-
rial and sera were obtained the same day as the
biopsies.
The presence of the cagA gene was detected by
PCR. Helicobacter pylori DNA was extracted by
boiling each strain suspension for 10min, followed
by centrifugation at 12 000 g for 15min. The super-
natant was then used as the PCR template. Two
pairs of previously described primers were used to
detect the two internal regions of the cagA gene
(GenBank accession no. U60176) [13]. First, 50-GAT
AACAGGCAACGT TTT CAGGGA-30 (positions
19119–19142) and 50-CCG AAC GGA TCA AAA
ATT CAT GG-30 (19512–19490), named cagA1 and
cagA2, respectively, were used to amplify a 394-bp
fragment of the cagA region [13] Second, 50-ATG
GGG AGT CAT GAT GGC ATA GAA CC-30
(19872–19897) and 50-GGT GGC TGT CTT TAA
TTT GCC TAA T-30 (20588–20564), named cagA3
and cagA4, respectively, were used to amplify a
717-bp fragment when the ﬁrst PCR was negative
[14]. PCR ampliﬁcation was performed in a ﬁnal
volume of 50 mL containing 5 mL of the diluted
DNA template (1/10, 1/100 and 1/1000) with a
10PCR buffer [670mM Tris–HCl (pH8.8),
160mM (NH4)SO2, 0.1% Tween]; 1.5mM MgCl2;
200 mM (each) of nucleotides dATP, dTTP, dGTP
and dCTP; and 1U of Taq polymerase (Eurobio,
Les Ulis, France); and with the speciﬁc primers.
PCR used 40 cycles of 1min at 94 8C, 1min at 58 8C,
and 1min at 72 8Cwith a ﬁrst cycle of 5min at 94 8C
and a ﬁnal cycle of 7min at 72 8C. Bands were
visualized on a 1% agarose gel stained with ethi-
dium bromide. Appropriate controls were always
run according to standard guidelines.
Standard methods were used to calculate sensi-
tivity, speciﬁcity and predictive values of positive
and negative results, as well as the 95% conﬁdence
intervals of these values. The ethical committee of
Bordeaux approved the protocol before the study
began.
Forty-eight of the 52 H. pylori-positive patients
had a positive culture: 39 had a cagA-positive
strain and nine a cagA-negative strain by PCR.
The primers cagA1,2 led to 34 positive results,
and ﬁve more positive cases were obtained with
the primers cagA3,4. CagA antibodies were found
in 44 of the 52 H. pylori-positive patients by Helico
Blot 2.1 (Figure 1).
Thirty-eight of the 39 patients with a cagA-posi-
tive strain presented CagA antibodies as well as
four of the nine patients with a cagA-negative
strain. Anti-CagA antibodies were also detected
in ﬁve of the 64 H. pylori-negative patients.
Considering the results obtained by PCR, Helico
Blot 2.1 gave a false-positive result for nine
patients and a false-negative result for one patient,
giving sensitivity, speciﬁcity, accuracy, positive
and negative predictive values for CagA status
with Helico Blot 2.1 of 97.4% (95% CI 84.9–99.9),
87.7% (95% CI 77.4–93.9), 80.9% (95% CI 66.3–90.4)
and 98.5% (95% CI 90.6–99.9), respectively.
The results of the different diagnostic methods
for the remaining four patients who were H. pylori
positive with a negative culture are presented in
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Table 1. No conﬁrmation of their Cag status could
be obtained.
Helico Blot 2.1 has the advantage of determining
the serological H. pylori status not explored in the
present work, and simultaneously determining
anti-CagA antibodies. Comparing our results with
those obtained by Yamaoka et al. using Helico Blot
2.0 [14], the performance of Helico Blot 2.1 was
highly improved, with an accuracy of 91% for the
latter compared to 70% for the former [14].
Since almost all the currently available diagnos-
tic methods have been used to determine the H.
pylori status of this group of patients, our data
show that a proportion of 7.8% (5/64) of subjects
without any evidence of actual H. pylori infection
have a serological reactivity against CagA. Three
of these ﬁve patients with anti-CagA antibodies
were also positive for anti-H. pylori IgG by ELISA,
indicating a possible immunological memory due
to a past H. pylori infection. This result is in agree-
ment with that of Fusconi et al. who, in a similar
study using the RIBA system, reported a propor-
tion of 10% of patients without any evidence of
current H. pylori infection with CagA antibodies
[12]. Indeed, CagA antibodies have been claimed
to be the last antibodies to disappear afterH. pylori
eradication.
With regard to the four H. pylori-positive
patients with a cagA-negative strain and a weak
reaction with the CagA band (116 kDa protein),
there may be a possible cross-reaction with other
proteins despite the fact that CagA has been
claimed to be a protein exclusive to H. pylori.
Alternatively, there could be a simultaneous infec-
tion with both cagA-positive and cagA-negative
strains, explaining the presence of antibodies in
the absence of PCR positivity. For further studies,
Southern hybridization using the entire PCR
Figure 1 Distribution of the results obtained for the 108 patients studied
Table 1 Results of Helicobacter pylori determination for four patients who were Helicobacter pylori positive with a negative
culture as evaluated by the analysis of all the diagnostic methods performed
Patient Histology CLOtest Culture
PCR/
biopsy
Urea
breath test
IgG/
ELISA
HELICO
BLOT 2.1
CagA
antibodies
1     þ þ þ þ
2 þ   þ þ þ þ þ
3 þ   þ þ þ þ þ
4     þ þ þ þ
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fragment as probe can eliminate the possibility of
PCR failure due to individual sequence variations
of the strains at the 30 end of the primers. Never-
theless, the high sensitivity, speciﬁcity and accu-
racy of the test for CagA antibodies compared to
the PCR results, showed that Helico Blot 2.1 is an
accurate, much improved version compared to
Helico Blot 2.0 and other tests cited in the literature
[14].
To establish the clinical interpretation and man-
agement of patients with anti-Cag antibodies and a
cagA-positive strain, larger studies are needed.
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